Table 3.
Effects of several inhibitors involved in TLR-2 signaling pathway on the activities of SERT, LDH, GSH and MDA level in MAP-infected Caco-2 monolayers in the presence of excess level (500 ng/mL) of 5-HT following 24 h of incubation.
| Treatment | SERT activity ± SD (% of control) | LDH activity ± SD (% of control) | GSH activity ± SD (% of control) | MDA level ± SD (uM) |
|---|---|---|---|---|
| Control (MAP + 500 ng/mL 5-HT) | 71.2 ± 1.5 | 89.7 ± 5.6 | 56 ± 1.7 | 91 ± 4.2 |
| TLR-2 Inhibitor (MMG 11 (5 ng/mL)) | 88.4 ± 2.7* | 39.2 ± 2.3* | 86.5 ± 3.4* | 34.1 ± 5.2* |
| ERK Inhibitor (PD 98059 (40 uM)) | 74.5 ± 1.4 | 79.1 ± 5.7 | 64.1 ± 1.7 | 79.2 ± 3.6 |
| p38 MAPK Inhibitor (SB 220025 (1 uM)) | 83.7 ± 1.9* | 47.4 ± 4.6* | 81.7 ± 2.6* | 39.4 ± 4.3* |
| cAMP/PKA Inhibitor (KT 5720 (1 uM)) | 76.1 ± 2.7 | 77.3 ± 1.9 | 68.9 ± 5.1 | 75.8 ± 1.7 |
| 5-HT3 Receptor Antagonist (Ondansetron (40 ng/mL)) | 81.4 ± 3.6* | 48.6 ± 2.8* | 79.3 ± 3.8* | 43.3 ± 2.9* |
Values were pre-tested for normal distribution using the Kolmogorov–Smirnov normality test. Significance among experiments was assessed by two-way analysis of variance (ANOVA) followed by Bonferroni correction test. All SERT, LDH, GSH, and MDA activity experiments were performed in triplicates. *P value < 0.05.